WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Strengthening Community responses to HIv Treatment and Prevention
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish
The report shows that where people and communities living with and affected by HIV are engaged in decision-making and HIV service delivery, new infections decline and more people living with HIV gain access to treatment. When people have the power to choose, to know, to thrive, to demand and to work... together, lives are saved, injustices are prevented and dignity is restored.
more
Dans la perspective d’une dynamique d’accélération du contrôle du paludisme en vue de l’atteinte du seuil épidémiologique de pré-élimination, le Ministère de la santé à travers le Programme National de Lutte contre le Paludisme (PNLP) a mis en œuvre plusieurs stratégies d’interve...ntion, en fonction des différentes cibles visées mais en relation avec la cartographie palustre. Ainsi, cette présente étude montre, les déterminants qui favorisent ou défavorisent l’adoption du comportement souhaité à l’endroit des cibles.
more
Le rapport 2016 fait état de la situation du VIH dans notre pays en rappelant les enjeux et défis en rapport avec le contexte international. Il renseigne également sur la situation du VIH, les financements et programmes mis en œuvre et les résultats obtenus.
Le rapport 2016 fait état de la situation du VIH dans notre pays en rappelant les enjeux et défis en rapport avec le contexte international. Il renseigne également sur la situation du VIH, les financements et programmes mis en œuvre et les résultats obtenus.
Antimicrobial resistance (AMR) is an important public health concern shared by developed and developing countries. In developing countries the burden of infectious diseases is greater and exacerbated by limited access to, and availability and affordability of, antimicrobials required to treat infect...ions caused by AMR organisms. With drugs not listed on the essential drugs list (EDL), problems of increased morbidity, costs of extended hospitalisation and mortality are extremely serious. The problem of susceptibility to and spread of infections caused by multidrug-resistant (MDR) infectious agents is fuelled by factors such as limited access to clean water and sanitation to ensure personal hygiene, malnutrition, and the HIV/TB epidemic.
more
Module 1
Clinical
July 2017
Module 1: Clinical. This module is for clinicians, including physicians, nurses and clinical officers. It gives an overview of how to provide PrEP safely and effectively, including: screening for substantial risk of HIV; performing appropriate testing before initi...ating someone on PrEP and while the person is taking PrEP; and how to follow up PrEP users and offer counselling on issues such as adherence.
more
Research Article
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002374 August 8, 2017
The United States Agency for International Development (USAID) Bureau for Democracy, Conflict, and Humanitarian Assistance Office of U.S. Foreign Disaster Assistance (DCHA/OFDA) requested Food and Nutrition Technical Assistance II Project (FANTA-2) assistance to review Community-Based Management of ...Acute Malnutrition (CMAM) in four West African countries—Burkina Faso, Mali, Mauritania, and Niger—to help identify DCHA/OFDA 2010 and 2011 program priorities, including where DCHA/OFDA investment should be directed to support CMAM. The goal was to review CMAM program implementation and its integration into national health systems to provide DCHA/OFDA a status report for each country; draw lessons learned; and make recommendations on challenges, promising practices, gaps, and priority areas for DCHA/OFDA support during 2010 and 2011. The review was intended for DCHA/OFDA program planning purposes and also potentially as an advocacy tool to guide other donors in planning CMAM support in the region. After all four countries have been reviewed, FANTA-2 will develop a synthesis report. The current document presents a summary report on CMAM in Burkina Faso only.
more
Research Article
Karo et al. BMC Infectious Diseases 2014, 14:148 http://www.biomedcentral.com/1471-2334/14/148